Clinical trial of methotrexate injection combined with mifepristone tablets in the treatment of placenta accreta
10.13699/j.cnki.1001-6821.2018.07.025
- VernacularTitle:甲氨蝶呤注射剂联合米非司酮片治疗植入性胎盘的临床研究
- Author:
Ying PENG
1
;
Da-Bao WU
;
Ling CHEN
Author Information
1. 安徽省立医院妇产科
- Keywords:
methotrexate injection;
mifepristone tablet;
placenta accreta;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(7):818-820
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of methotrexate injection combined with mifepristone tablets in the treatment of placenta accreta.Methods A total of 50 pregnant women with placenta were randomly divided into control group (n =24 cases) and treatment groups (n =26 cases).Control group was treated with routine hemostasis,contractions and anti-infection.Treatment group was given methotrexate 60 mg per time,qd,injected near the placenta accreta under ultrasound guidance + mifepristone 50 mg per time,bid,orally,on the basis of control group,for 10 days.The placenta discharge time,vaginal bleeding,endometrial recovery time,days of uterine involution and adverse drug reactions were compared between two groups.Results After treatment,the main indexes in treatment and control groups were compared:placenta discharge time were (11.21 ± 4.15) and (15.83 ±3.92) d,vaginal bleeding were (742.56-± 105.60) and (891.52 ± 125.44) mL,endometrial recovery time were (20.14 ± 3.53) and (24.95 ±2.87)d,days of uterine involution were (22.12 ±2.86) and (26.83 ± 3.25) d,the differences were statistically significant (all P ＜0.05).The adverse drug reactions in treatment group were liver injury,digestive tract reaction and oral ulcer,which in control group were liver injury.The total incidences of adverse drug reactions in treatment and control groups were 15.38％ and 8.33％ without significant difference (P ＞ 0.05).Conclusion Methotrexate injection combined with mifepristone tablets has a definitive clinical efficacy in the treatment of placenta accreta,without increasing the incidence of adverse drug reactions.
